Evidence map›Paper›PMID 35688909›Full record

ArticleNature communications2022

Iridium-catalyzed direct asymmetric reductive amination utilizing primary alkyl amines as the N-sources.

Zitong Wu, Wenji Wang, Haodong Guo, Guorui Gao, Haizhou Huang, Mingxin Chang

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Electrophilicity Modulation for Sub-ppm Visualization and Discrimination of EDA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zitong Wu *College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, China.
Wenji Wang *College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, China.ORCID 0000-0002-3607-1252
Haodong GuoCollege of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, China.
Guorui GaoCollege of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Shandong Normal University, 88 Wenhuadong Road, Jinan, 250014, China.
Haizhou HuangCollege of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, China.ORCID 0000-0002-1611-9829
Mingxin ChangCollege of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, China. mxchang@nwsuaf.edu.cn.ORCID 0000-0002-5407-3403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct asymmetric reductive amination is one of the most efficient methods for the construction of chiral amines, in which the scope of the applicable amine coupling partners remains a significant challenge. In this study we describe primary alkyl amines effectively serve as the N-sources in direct asymmetric reductive amination catalyzed by the iridium precursor and sterically tunable chiral phosphoramidite ligands. The density functional theory studies of the reaction mechanism imply the alkyl amine substrates serve as a ligand of iridium strengthened by a (N)H-O(P) hydrogen-bonding attraction, and the hydride addition occurs via an outer-sphere transition state, in which the Cl-H H-bonding plays an important role. Through this concise procedure, cinacalcet, tecalcet, fendiline and many other related chiral amines have been synthesized in one single step with high yields and excellent enantioselectivity.

Indexed as

AminesIridiumAminationCatalysisLigandsAminesIridiumLigands

Identifiers

PMID35688909
PMCPMC9187633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.